Farydak
Description
Farydak is a cancer medicine used in combination with two other medicines, bortezomib and dexamethasone, to treat multiple myeloma (a cancer of the bone marrow). Farydak contains the active substance Panobinostat.
Qualitative and quantitative comnposition
Each hard capsule contains panobinostat lactate anhydrous equivalent to 10 mg, 15 mg or 20 mg Panobinostat.
Pharmaceutical form
Hard capsule.
Farydak 10 mg hard capsules Light green opaque hard gelatin capsule (15.6–16.2 mm) containing white to almost white powder, with radial marking “LBH 10 mg” in black ink on cap and two radial bands in black ink on body.
Farydak 15 mg hard capsules Orange opaque hard gelatin capsule (19.1–19.7 mm) containing white to almost white powder, with radial marking “LBH 15 mg” in black ink on cap and two radial bands in black ink on body.
Farydak 20 mg hard capsules Red opaque hard gelatin capsule (19.1–19.7 mm) containing white to almost white powder, with radial marking “LBH 20 mg” in black ink on cap and two radial bands in black ink on body.
Nature and contents of container
PVC/PCTFE/Alu blister containing 6 capsules.
For more information
SE: https://www.fass.se/LIF/startpage
NO: https://www.felleskatalogen.no
DK: http://www.produktresume.dk
FI: https://www.fimea.fi